Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
RBC8
Cat. No.:
OB0225LY-0067
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
RBC8 is a small molecule drug that targets specific cancer-related biomarkers to selectively target and inhibit tumor growth.
CAS No.:
361185-42-4
Formula:
C25H20N4O3
Formula Weight:
424.45
Specification
Relative Density:
1.40 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
RBC8 can be used to specifically inhibit the GTPases RalA/RalB.
Library Information
Targets:
GTPase superfamily
Receptors:
GTPases RalA; GTPases RalB; Ras
Pathways:
GPCR/G protein; MAPK
Plate Number:
AOCL-1
Plate Location:
g9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
42.4 mg/mL; 100 mM
